FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Topics >> Provenge | Dendreon

Dendreon plays waiting game as Provenge deadline looms

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


Sometime by the end of tomorrow, the FDA should deliver its final decision on Dendreon's (NASDAQ: DNDN) Provenge, a potential breakthrough therapeutic cancer vaccine. (The official deadline is on Saturday.) In the meantime, the Seattle-based developer has reaped a bumper crop of news reports focused on the potential benefits the therapy could offer prostate cancer victims. Virtually every major news outfit in the country--along with a host of smaller media outlets--has previewed the therapy in the past week.

"It is certainly exciting to see a drug that has made it this far and appears on the threshold of approval," Dr. J. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, tells HealthDay.

Dendreon has had to battle back from a three-year delay in its original schedule for a decision after the FDA ignored an expert panel recommendation for approval and demanded another late-stage study of the cancer vaccine. In patients with advanced prostate cancer, the therapy generated new data demonstrating a modest improvement in survival without slowing disease progression. Doctors may also use it at an earlier disease stage, though, when it could prove more beneficial.

If it is approved, Provenge will become the key trendsetter for all the rest of the therapeutic vaccines in the pipeline. The vaccine is made with a patient's own white cells, and at an expected cost of $75,000 in return for an average 4.5 months of extra life, Provenge will test just how much insurers are willing to pay for incremental cancer benefits.  

- here's the story from HealthDay

Related Articles:
Sanofi exec, Novartis pipeline snag vaccine awards
Researchers see cancer vaccine revolution on the horizon
Dendreon tripling workforce ahead of expected vax launch
Dendreon files Provenge BLA

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Comments (1) | Post a comment
More stories about Provenge   Dendreon  


At last, the approval of Provenge to use for prostrate cancer treatment has been approved by the FDA. Dendreon Provenge is a post cancer shot that is meant to increase the life span of a patient with prostate cancer. Patients' life spans are said to increase 4.1 months when using this vaccine. Although that may not seem like long to some, it is a lifetime to others. Besides, this new vaccine is really a huge discovery, and opens the doors to opportunities of better and more successful treatments within the future.

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.